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A B S T R A C T
Introduction: Acute upper respiratory tract infections (URTIs) are very common diseases. Qingkailing
injection (QKL) has been widely used in China for uncomplicated URTIs. However, the evidence of the
effect of QKL has not been assessed systematically. We therefore performed a systematic review in an
attempt to evaluate the efﬁcacy and safety of QKL for uncomplicated URTIs in children and adults.
Methods: Eight databases (Western and Chinese) were extensively searched from inception to January
2016 for relevant randomized controlled trials (RCTs). Two reviewers independently extracted data and
assessed the quality of studies according to the Cochrane standards. Meta-analysis was carried out using
Review Manager Software (version 5.3), provided by the Cochrane Collaboration.
Results: Twenty-six studies involving 3121 participants were included in this systematic review. Meta-
analysis showed that QKL plus western medicine signiﬁcantly improved the effective rate
(Heterogeneity: x2 = 17.25, P = 0.70, I2 = 0%; RR = 1.19; 95% CI = [1.15, 1.23]; P < 0.00001) and the duration
of clinical symptoms compared with western medicine alone. There were seventeen studies mentioned
adverse drug reactions (ADRs). A pooled analysis showed that there was a slightly raised risk of ADRs in
western medicine group (Heterogeneity: x2 = 7.27, P = 0.51, I2 = 0%; RR = 0.39; 95% CI = [0.22, 0.69];
P = 0.001).
Conclusions: In summary, there is some encouraging evidence for the use of QKL for uncomplicated URTIs.
However, we still cannot draw deﬁnitive conclusions due to the poor methodological quality of included
studies. More high-quality RCTs would help to conﬁrm the evidence.
ã 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Acute upper respiratory tract infections (URTIs), which include
common cold, inﬂuenza, inﬂammation of the larynx and pharynx,
acute otitis media and rhino sinusitis, are very common diseases
and the major cause of absenteeism from work and school [1].
Typical symptoms are fever, sneezing, runny nose, cough,
headache, and sore throat [2]. URTIs are often caused by viral
infections. In patients with uncomplicated URTIs (common cold),
viruses characteristically cause an infection that is mild, self-
limited and of short duration [3,4]. However, sometimes, the
infection spreads to adjacent organs, resulting in various clinical
complications and an enormous economic burden on society [5,6].
Due to the various pathogenetic mechanisms caused by a
multitude of different virus types, no effective universal treatment
is available at present [7]. Although being widely used in the
treatment of uncomplicated viral URTIs, antibiotics are not
effective against viruses [8,9]. Early antibiotic treatment of URTIs
does not appear to prevent pneumonia or acute otitis media in
children [10]. According to recent meta-analyses, there is no
evidence of beneﬁt from antibiotic treatments for uncomplicated
URTIs in children and adults [11]. Routine use of antibiotics for
nonspeciﬁc URTIs is not recommended [12,13].
Angong Niuhuang Pill, a well-known compound formula of
Traditional Chinese Medicine (TCM), consists of Acidum cholicum,
Acidum hyodesoxy-cholicum, Cornu Bubali, Concha Margaritifera,
Flos lonicerae, baicalinum, Fructus gardenise and Radix Isatidis [14].
Qingkailing injection (QKL) is extracted from Angong Niuhuang Pill
and has been widely used in the clinic for treating stroke,
cardiovascular disease, acute hepatitis, chronic hepatitis and URTIs
[15]. It was approved by China Food and Drug Administration
(CFDA) since 2002 and was included in “National Essential Drug
List” (2004 Edition) [16,17]. In mainland China, QKL was well
known for its remarkable effect of antipyretic action and enormous
market share [18–21]. Clinical trials reported that QKL could
alleviate the symptoms of uncomplicated URTIs. Pharmacological
studies proved that QKL could reduce fever, anti-viral and anti-
bacterial and it also could inhibit the metabolic behavior of S.
aureus. Animal studies indicated that QKL probably exerted its
antipyretic effect by repairing the perturbed metabolism of amino
acids [22].
The availability of scientiﬁc evidence is the major obstacle for
the acceptance of TCM in western countries. Previous meta-
analyses have been conducted to evaluate the effect of QKL in
treating acute stroke [23–26]. So far, there has been no systematicreview of randomized controlled trials of QKL in treating
uncomplicated URTIs or common cold. Therefore, we performed
a systematic review in an attempt to better deﬁne the efﬁcacy and
safety of QKL in the treatment of uncomplicated URTIs.
2. Materials and methods
The current review was performed following the criteria of
PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) [27] and AMSTAR (Assessment of Multiple
Systematic Reviews) [28] through all stages.
2.1. Data sources and search strategy
For this systematic review we searched the following 8
databases: Cochrane Central Register of Controlled Trials, Medline
(via PubMed), Science Citation Index (SCI), Clinicaltrials.gov,
Chinese National Knowledge Infrastructure (CNKI), Wanfang Data,
Sino-Med database, the VIP Chinese Scientiﬁc Journal database
(CQVIP). The last search was updated on January 2016. Search term
‘Qingkailing’ was combined with the following keywords respec-
tively: ‘upper respiratory tract infection’; ‘URTI’; ‘common cold’;
‘cold’; ‘shang feng’; ‘wai gan’; ‘feng han’ and ‘random*’. We also
searched for these terms in the titles and abstracts. When an
abstract did not contain such data; but the presence of such data
was expected in the full-text paper; the full-text paper was
screened as well.
2.2. Study selection criteria
All studies were included for this systematic review if they met
the following inclusion criteria: (1) The study was a randomized
controlled trial. (2) Participants in the studies were diagnosed with
URTIs or common cold, without other speciﬁcally deﬁned
respiratory conditions, for example tonsillitis, laryngitis, pneumo-
nia, bronchitis and asthma. Diagnostic criteria and treatment
efﬁcacy evaluation system followed the Guidelines for Clinical
Research of New Chinese Medicine (GCRNCM) and Criteria of the
Diagnosis and Curative Effect of Common Diseases (CDCECD) [29].
Given the deﬁnition of URTIs is hard to apply rigidly, the
researchers also accepted trials in which the diagnosis was made
on textbooks and clinical grounds. (3) QKL was used in the
experimental group without other TCM. We included trials
allowing concurrent use of western medicine if they equally used
in both experimental group and control group. Western medicine
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treatments. Conventional treatments included anti-infectious
agent, cough suppressant, expectorant, analgesic-antipyretic
medicine. (4) The primary outcome measure is effective rate
(which was based on the proportion of participants with resolution
or improvement of symptoms). We converted these outcomes to
dichotomous data in meta-analyses. Secondary outcomes were
adverse drug reactions (ADRs), white blood cell counts (WBC) and
related clinical symptoms. There were no restrictions on gender,
language, or publication type.
2.3. Data selection and extraction
Two researchers (P. Wang and L.H. Li) independently searched
the databases and reviewed the title and abstracts of the electronic
search results to select relevant records. One researcher (L. H. Li)
obtained the full text of the articles. Data was extracted by two
researchers (P. Wang and L. H. Li) using a standard form included
authors information, year of publication, participant related
information (age, sex and number), details of interventions,
outcomes, results, and ADRs. Given the diversity of participants
at different ages, two spreadsheets were formed respectively for
children (aged 0–14 years) and adults (older than 14 years).
Disagreements were resolved by discussion with a third researcher
(X. Liao). The reviewers were not blinded to the journal of origin,
the authors or the results.Fig 1. Flow chart of study2.4. Quality assessment and statistical analyses
We used the Cochrane ‘Risk of bias’ tool for assessing bias with
consideration of: adequate random sequence generation, alloca-
tion concealment, adequate blinding, incomplete outcome data
and selective reporting. The two researchers (P. Wang and L. H. Li)
independently assessed the quality of included articles and
disagreements were resolved by discussion.
Meta-analysis was carried out using Review Manager Software
(version 5.3), provided by the Cochrane Collaboration. Statistical
heterogeneity was assessed according to the “Cochrane Handbook
of Systematic Review of Interventions (version 5.1.0)”. We assessed
heterogeneity using the I-squared (I2) statistic. If there was obvious
large heterogeneity, the group was divided into subgroups with
similar characteristics to ﬁnd out reasons for heterogeneity. If the
heterogeneity could not be resolved (when the I2 statistic was over
50%), meta-analysis would not be conducted. Dichotomous data
were presented as risk ratios (RR) and continuous data as mean
difference (MD), both with 95% conﬁdence interval (CI).
The twenty-six included trials differed in the ages and the types
of intervention. Therefore, subgroup analyses were performed on
intervention type of the treatment group. In each subgroup,
participants were further divided into children, adults and all ages.
The results were summarized through forest plots. We performed a
funnel plot of effective rate between QKL plus western medicine
group and western medicine group to assess the publication bias. search and selection.
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3.1. Description of included studies
A total of 5253 records were identiﬁed through electronic
databases. A single ongoing study was identiﬁed through Clinical
Trials.gov. After removing duplicates, we screened 2227 records
through titles and abstracts and selected 199 for full-text
assessment. There were 41 nonrandomized controlled trials, 130
trials with inappropriate populations/interventions/outcomes,
and 2 trials with incomplete data. In the end, twenty-six trials
(all published in Chinese) met the inclusion criteria (Fig. 1). The
characteristics of the 26 included studies (thirteen studies for
children aged 0–14 years and thirteen studies for adults older than
14 years) are given in Table 1 and Table 2.
The included trials enrolled 3121 participants (1636 in
experimental group and 1485 in control group) with clinical
symptoms of uncomplicated URTIs. The diagnosis of URTIs were
based on Guidelines for Clinical Research of New Chinese Medicine
(GCRNCM) [32,42], Criteria of the Diagnosis and Curative Effect of
Common Diseases (CDCECD) [45,52], Internal Medicine (IM) [54],
Practice of Internal Medicine (PIM) [49], Essentials of Internal
Medicine (EIM) [47], Pediatrics (PED) [37], Practice of Pediatrics
(PP) [34,35,40,41] and Pediatric Diagnosis and Treatment (PDT)Table 1
Characteristics of 13 included studies on QKL for URTIs (children).
Author (year) Sample size (EG/
CG)
Age(year) Range
(mean)
Sex (Male/
Female)
Interv
Guo et al. [30] 50/50 (1.0) EG:27/23 EG:QK
CG:29/21 CG:V +
Mo and Zhang
[31]
40/40 NA EG:25/15 EG:QK
CG:NA CG:V 
Liu [32] 48/47 0.7–14 50/45 EG:QK
CG:V +
Wang [33] 52/52 0.5–8 44/60 EG:QK
CG:V +
Xu [34] 38/37 EG:0.5–14(3.2) 40/35 EG:QK
CG:0.5–14(3.5) CG:V +
Liu and Liu [35] 60/60 0–14 EG:36/24 EG:QK
CG:32/28 CG:V +
Zhang et al. [36] 68/71 1–14 EG:38/30 EG:QK
CG:48/23 CG:V +
Zhang and Yan
[37]
80/80 1–14 EG:44/36 EG:QK
CG:42/38 CG:V +
Guo and Liu [38] 98/80 3.3–7.5(4.8) EG:52/46 EG:QK
CG:42/38 CG:CE
Yu [39] 64/62 0.7–3 EG:33/31 EG:QK
CG:30/32 CG:AN
C,E)
Ye [40] 65/55 2–14 72/48 EG:QK
CG:V +
Deng [41] 158/72 0.5–3 EG:118/40 EG:QK
CG:NA CG:CT
Wu [42] 32/28 2.5–9 EG:17/15 EG:
QKL + 
CG:14/14 CG:V +
(A)
Note: EG: experimental group; CG: control group; a: gastrointestinal symptoms; b: dizzin
C: cough suppressant; D: expectorant; E: analgesic-antipyretic medicine; V: Virazole; E
symptoms; CEF: cefuroxime; ANT: antondine; PEN: penicillin.[30]. Participants in six trials were diagnosed based on clinical
symptoms [41,36,48,50,51,53]. Participants in seven trials were
claimed being diagnosed with URTIs, but the authors did not report
the speciﬁc diagnostic criteria [16,38,39,43,44,46,55]. The patients
ranged from 0 to 79 years old. Thirteen of the trials in this review
included children only (as shown in Table 1) and seven trials
included adults only. Three trials included both children and
adults. Two trials provided the average age of all participants
without the information of range. Information of age in one study
was not available.
All trials used QKL alone or combined with western medicine in
the experimental group. The interventions for control group were
only western medicine treatments, including symptomatic treat-
ment, anti-infectious agent, cough suppressant, expectorant,
analgesic-antipyretic medicine, dexamethasone and virazole (as
shown in Table 1 and Table 2). The dose of QKL ranged from 0 ml to
40 ml and the route of administration was intravenous drip. The
treatment duration varied from 3 to 7 days.
All studies used effective rate as an outcome measure except
one performed in 2006 [55], which only reported the time for body
temperature recovery and symptomatic resolution. Eight trials
reported the duration of clinical symptoms, including fever,
headache, sore throat, stuffy nose, cough and adenoids. White
blood cell count test were conducted in two trials.ention Drug Dose Treatment Duration
(day)
ADRs(n) Outcomes
L + CT EG:0.8–1 ml/kg 3–5 NA ER, DS
 CT CG:10–15 mg/
kg
L EG:3–10 ml 3–5 EG:h(1)
CG:NA
ER
CG:10–15 mg/
kg
L + CT EG:0.8 ml/kg 3–5 None ER
 CT(B) CG:10–15 mg/
kg
L + CT EG:0–4 ml/kg EG:3–5 EG:a(6) ER
 CT(B,C,D) CG:10–20 mg/
kg
CG:7 CG:a(5)b(2)h
(1)
L + CT EG:0.4 ml/kg 3–5 None ER
 CT(B,C,D) CG:10–15 mg/
kg
L + CT EG:1 ml/kg 3–5 NA ER
 CT(A,B) CG:10 mg/kg
L + CT EG:0.8 ml/kg EG:3 None ER
 CT(A) CG:10–15 mg/
kg
CG:3–5
L + CT EG:10–20 ml 3 None ER
 CT(B,E) CG:NA
L + CEF + CT EG:1 ml/kg NA NA ER, DS
F + CT(E) CG:200 mg/kg
L + CT EG:0.8–1.2 ml/
kg
NA EG:a(3) ER
T + CT(A,B, CG:0.1–0.15 ml/
kg
CG:a(3)h(1)
L + CT EG:8–20 ml NA EG:a(1) ER
 CT(A) CG:10–15 mg/
kg
CG:a(3)
L + CT EG:6–14 ml NA EG:c(1) ER
(A,B) CG:NA CG:NA
PEN + CT
EG:1 ml/kg NA NA ER, DS
 PEN + CT CG:NA
ess; c: skin itching; h: eruption; A: symptomatic treatment; B: anti-infectious agent;
R: effective rate; NA: not applicable; CT: conventional treatment; DS: duration of
Table 2
Characteristics of 13 included studies on QKL for URTIs (adult and all ages).
Author (year) Sample size(EG/CG) Age (year)
Range (mean)
Sex
(Male/Female)
Intervention Dose Treatment
Duration(day)
ADRs(n) Outcomes
Yang [43] 44/44 EG:18–70(52.5) EG:24/20 EG:QKL EG:20 ml 7 EG:a(2)b(1) ER
CG:20–72(54.2) CG:22/22 CG:AZI CG:20 ml CG:a(7)b(5)f(3)i(3)
Yu [44] 82/78 EG:18–50(34.5) EG:42/40 EG:QKL + CT NA 3–7 NA ER, WBC
CG:19–52(35.5) CG:41/37 CG:CT(B,C,E)
Wu [45] 84/84 EG:14–69(34.0) EG:48/36 EG:QKL + CT EG:35–40 ml 3–5 EG:c(1) ER, DS
CG:15–68(34.0) CG:45/39 CG:V + CT(E) CG:10 mg/kg CG:d + e(1)
Yang [46] 102/101 EG:19–63 EG:57/55 EG:QKL EG:30 ml NA EG:b(1) ER
CG:18–62 CG:58/53 CG:V CG:1g CG:a(1)g(3)
Fan and Liu [47] 45/45 EG:18–49(29.8) EG:24/21 EG:QKL + CT EG:20 ml 7 None ER, DS
CG:20–47(27.9) CG:22/23 CG:CT CG:NA
Zeng [48] 64/60 EG:18–34(21.3) EG:33/31 EG:QKL + CT EG:40 ml 5 NA ER
CG:18–35(20.1) CG:31/29 CG:CT(V,D,E) CG:NA
Zhang [49] 33/33 EG:60–73(68.4) EG:20/13 EG:QKL + CT EG:40 ml 3–5 NA ER
CG:61–79(69.5) CG:19/14 CG:CT(V,D,E) CG:NA
Wang [50] 63/63 3–68 EG:32/31 EG:QKL + CT EG:6–40 ml 3–5 EG:c(1) ER, DS
CG:34/29 CG:PEN/LIN + CT CG:NA CG:d + e(2)
Bao [51] 40/40 3–60 EG:22/18 EG:QKL + CT EG:5–30 ml NA NA ER
CG:19/21 CG:V + PEN + CT CG:NA
Wang [52] 60/60 EG:3–68 EG:33/27 EG:QKL + CT EG:6–40 ml 3–5 EG:c(1) ER, DS
CG:3–69 CG:31/29 CG:V + CT(E) CG:10 mg/kg CG:d + e(1)
Li [53] 56/32 EG:(32.6) EG:32/34 EG:QKL EG:40 ml 3 NA ER, WBC, DS
CG:(33.4) CG:17/15 CG:LIN CG:1.8g
Lu [54] 28/29 EG:(24.8) EG:12/16 EG:QKL + CT EG:20–40 ml 3–5 EG:None ER, DS
CG:(25.3) CG:14/15 CG:V + CT(A,C,D) CG:NA CG:a(2)
Pei [55] 82/82 NA NA EG:QKL EG:20–40 ml NA EG:a(5)c(3) DS
CG:V + CT(DEX) CG:5–10 mg/kg CG:NA
Note: EG: experimental group; CG: control group; a: gastrointestinal symptoms; b: dizziness; c: skin itching; d: ﬂushing; e: dry mouth; f: insomnia; g: fatigue; h: eruption; A:
symptomatic treatment; B: anti-infectious agent; C: cough suppressant; D: expectorant; E: analgesic-antipyretic medicine; V: Virazole; ER: effective rate; NA: not applicable;
CT: conventional treatment; WBC: white blood count; DS: duration of symptoms; AZI: azithromycin; PEN: penicillin; LIN: lincomycin; DEX: dexamethason.
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The methodological quality in the included studies was
assessed according to the criteria in the “Cochrane Handbook
for Systematic Review of interventions” [56]. The methodological
quality of most studies was “poor”. All of the included studies
stated randomization but did not describe the method. None of the
studies mentioned the methods of allocation concealment or
blinding (patients, clinicians or outcome assessors). None of the
studies reported information on follow-up. One study provided0.5 0.7 
0
0.05
0.1
0.15
0.2
SE(log [RR ])
Fig. 2. Funnel plot of 22 randomized controlled trials for the outcomes of effectiveinconsistent data, in which the number of participants in QKL
group changed from 44 to 42 after treatment without any
discussion [43]. The rest of included studies had not lost
participant. We considered trials as having low risk of bias to
selective reporting if they reported all pre-speciﬁed outcomes in
the method section. According to this, eight studies had low risk of
bias [30,44–47,52–54]. Two trials claimed to carry out chest X-rays
without reporting the results [43,50]. Selective reporting in other
studies was unclear due to the unavailability of the research
proposal. None of the studies described sample size calculation.1 1.5 2
RR
 rate between QKL plus western medicine group and western medicine group.
614 L. Li et al. / European Journal of Integrative Medicine 8 (2016) 609–618A funnel plot revealed an asymmetrical distribution of studies
for effective rate between QKL plus western medicine group and
western medicine group (Fig. 2). These twenty-two trials were all
published in Chinese and most of them reported positive results,
which indicated that there is publication bias.
3.3. Effective rate
There were 25 studies (including a total of 2957 participants)
reported effective rate as primary outcome measure, which was
based on the proportion of participants with resolution orStud y or Subg rou p
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Fig. 3. Forest plot of comparison: QKL plus western medicine veimprovement of symptoms, according to the criteria in GCRNCM.
Total effective rate is the combination of cure rate (temperature
returned to normal within 3 days and all of the clinical symptoms
and physical signs were completely resolved), signiﬁcant effective
rate (temperature returned to normal within 3 days and most of
the main clinical symptoms and physical signs were resolved) and
effective rate (temperature went down within 3 days and part of
the main clinical symptoms and physical signs were reduced). We
converted these outcomes to dichotomous data in meta-analyses.
We performed separate analyses by subgroups (based on
various comparisons and ages).ndo m, 95% CI
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Three trials [43,46,53] contributed to this meta-analysis, giving
an overall sample of 379 adult participants (202 in the
experimental group and 177 in the control group). They all
compared the effect of QKL individually versus western medicine.
There was a signiﬁcant heterogeneity, so meta-analysis was not
conducted. Two studies [46,53] compared the effects of QKL with
virazole and lincomycin respectively. They found that participants
in QKL group showed signiﬁcant improvements in efﬁcacy rate,
compared with control groups. One study [43] compared the
effects of QKL with azithromycin. The results showed no signiﬁcant
differences in effective rate, but there was a slightly raised risk of
ADRs in azithromycin group.
3.3.2. QKL plus western medicine versus western medicine
A total of 22 trials (involving 2578 participants) investigated the
effect of QKL plus western medicine versus western medicine
alone. We divided the trials into three subgroups and analyzed the
results separately: children group, adults group and all age group
(children and adults were both included). The results showed that
QKL plus western medicine were signiﬁcantly better than western
medicine alone on improving the outcome effective rate (Hetero-
geneity: x2 = 17.25, P = 0.70, I2 = 0%; RR = 1.19; 95% CI = [1.15, 1.23];
P < 0.00001). The RR was 1.18 in children group (95% CI = [1.14,
1.23]; P < 0.00001), 1.20 in adults group (95% CI = [1.12, 1.28];
P < 0.00001), and 1.29 in all age group (95% CI = [1.04, 1.60];
P = 0.02) (Fig. 3).Fig. 4. Forest plot of comparison: QKL plus western medicine3.4. Duration of clinical symptoms
Eight trials (involving 963 participants) reported the effective-
ness of QKL plus western medicine versus western medicine alone
on the duration of symptoms (including fever, headache, sore
throat, stuffy nose, cough and adenoids). The units for these data
were all converted to days.
3.4.1. Fever
All of the eight trials (two trials for children, four trials for adults
and two trials for mixed ages) reported the duration of fever. Meta-
analysis was conducted in subgroups (Children: x2 = 0.19, P = 0.66;
I2 = 0%; Mixed ages: x2 = 0.23, P = 0.63; I2 = 0%). In children group,
the results showed a signiﬁcant increase of symptom improvement
in experimental group compared to control group (MD = 0.84;
95% CI = [1.19, 0.48]; P < 0.00001). In mixed ages group, the
effect was also positive for experimental group (MD = 2.04; 95%
CI = [2.25, 1.83]; P < 0.00001). As for the adults, the results
showed that QKL was effective in reducing fever in each trial, but
meta-analysis was not conducted due to the obvious large
heterogeneity (x2 = 162.81, P < 0.00001; I2 = 98%).
3.1.1. Headache
Three trials [47,50,52] reported the duration of headache. One
trial for adults [47] showed that the combination of QKL and
western medicine therapy was better than western medicine alone
in relieving headache. A pool analysis of trials in mixed ages [50,52]
showed that QKL plus western medicine signiﬁcantly reduced the versus western medicine, at different age stages, ADRs.
616 L. Li et al. / European Journal of Integrative Medicine 8 (2016) 609–618duration of headache (Heterogeneity: x2 = 0.96, P = 0.33, I2 = 0%;
MD:1.53; 95% CI = [1.73, 1.33]; P < 0.00001).
3.4.3. Sore throat
Two trials [50,52], in which the patients included both children
and adults, provided data for the duration of sore throat. The result
showed that QKL plus western medicine had more beneﬁt
compared with western medicine alone (Heterogeneity:
x2 = 0.12, P = 0.73, I2 = 0%; MD:1.90; 95% CI = [2.02, 1.79];
P < 0.00001).
3.1.2. Stuffy nose
Three trials [47,50,52] compared the effect of QKL plus western
medicine versus western medicine alone on the duration of stuffy
nose. One trial for adults [47] showed QKL plus western medicine
therapy was better than western medicine alone in the resolution
of stuffy nose. A pool analysis of trials in mixed ages [50,52]
showed that there were signiﬁcantly differences between the
experimental group and control group. The result was in favor of
QKL plus western medicine therapy (Heterogeneity: x2 = 0.00,
P = 1.00, I2 = 0%; MD: 1.47; 95% CI = [1.65, 1.29]; P < 0.00001).
3.4.5. Cough
Three trials [47,50,52] reported the effectiveness of interven-
tions on cough. Although the individual trials were all favored of
QKL group on the effect of relieving a cough, we did not calculated
the pooled effects due to the considerable heterogeneity (Hetero-
geneity: x2 = 19.03, P < 0.0001, I2 = 89%).
3.4.6. Adenoids
Two trials [50,52] in which the patients included both children
and adults, reported the duration of adenoids. The result was in
favor of QKL plus western medicine therapy (Heterogeneity:
x2 = 1.21, P = 0.27, I2 = 17%; MD:1.18; 95% CI = [1.38, 0.99];
P < 0.00001).
3.2. White blood cell count
Two trials [44,53] mentioned white blood cell count. As
reported, the count of white blood cell was similar between the
comparison groups after treatment
3.2.1. Adverse drug reactions (ADRs)
Seventeen trials (involving 2145 patients) mentioned the
occurrence of ADRs and the other nine trials provided no data
about ADRs. The ADRs included gastrointestinal symptoms,
dizziness, skin itching, ﬂushing, dry mouth, insomnia, fatigue,
skin eruption and increased AST. Five trials reported that there
were no ADRs.
In the comparison of QKL and western medicine therapy, one
trial [31] on children reported the appearance of skin eruption
after treating with QKL for three days, which disappeared after
stopping medicine. One trial [54] on adult reported two patients in
conventional treatment group appeared nausea and recovered
after symptomatic treatment. One trial [55] on adult reported 8 out
of 82 patients in QKL group appeared stomach upset and skin
itching and recovered when the drug were removed.
Meta-analysis was conducted to compare the ADRs in QKL plus
western medicine group and western medicine alone group. No
signiﬁcant differences were found in ADRs between these two
groups among children (Heterogeneity: x2 = 0.81, P = 0.85, I2 = 0%;
RR = 0.65; 95% CI = [0.29, 1.45]; P = 0.29) and mixed ages (Hetero-
geneity: x2 = 0.14, P = 0.71, I2 = 0%; RR = 0.66; 95% CI = [0.11, 4.03];
P = 0.71). However the result for adults revealed that ADRs were
slightly more common in control group (Heterogeneity: x2 = 2.14,
P = 0.34, I2 = 7%; RR = 0.17; 95% CI = [0.06, 0.47]; P = 0.0006). Fig. 4showed that ADRs of western medicine therapy were a little more
than that of QKL plus western medicine group (Heterogeneity:
x2 = 7.27, P = 0.51, I2 = 0%; RR = 0.39; 95% CI = [0.22, 0.69]; P = 0.001).
No serious ADR was reported.
4. Discussion
TCM injection is a quick-acting form of Chinese herbal
medicine, which is widely used in the treatment of acute, severe
diseases in mainland China [57]. According to CFDA, 147 kinds of
Chinese herbal injections, with the sales exceeding two billion U.S.
dollars per year, were used between 2004 and 2007 in modern
Chinese hospitals [58,59]. However, it is controversial in western.
Researchers have already paid attention to the safety of TCM
injection, especially after the consecutive reports of ADRs recently
[60,61]. It is important to perform objective reviews to investigate
both of the therapeutic beneﬁts and the safety concerns of TCM
injection.
To date, there has been no systematic review of efﬁcacy and
safety of QKL in uncomplicated URTIs or common cold. The
effectiveness of QKL in treating acute stroke had been systemati-
cally reviewed in previous studies [23,24]. Two systematic reviews
[25,26], which were both published in Chinese, investigated the
effect of QKL in respiratory tract infections (RTIs).The conclusion of
the two studies were that QKL has beneﬁcial effects on RTIs.
However, there are some deﬁciencies in the two studies mentioned
above. For example, the criteria of diagnosis and curative effects of
the two studies were undeﬁned. The study [26] did not provide the
list of included trials for readers to evaluate the scientiﬁcity of the
review. The study [25] included several trials in which an overdose
of QKL was applied and this may mislead doctors’ clinical practice.
Unlike previous reviews, in which participants of URTIs was not
classiﬁed according to age, the current review was performed into
three subgroups (children group, adults group and all age group) to
evaluate effectiveness and safety of QKL. In addition, many trials
were carried out in recent three years and we added them in the
current review. These improvements could increase the accuracy
of assessment of the effectiveness of QKL in treating uncomplicat-
ed URTIs.
We performed a series of meta-analyses involving a total of
2957 participants. All the included trials were conducted in China.
Children and adults may have been different responses to the
treatment. So we performed subgroup analyses to ﬁnd out the
differences. Three trials included both children and adults, but did
not report the respective number of children or adults. Two trials
provided the average age of all participants without the informa-
tion of age range. Information of ages in one study was not
available. Thirteen trials only included children, and the other
seven trials included only adults. The results indicated that QKL
plus western medicine therapy signiﬁcantly improved the clinical
efﬁcacy rates in children, adults and all age groups. The result was
similar at different age stages, and this might be due to the
disproportion trial number of each age stage and the low quality of
included trials.
Meta-analysis showed that QKL plus western medicine were
signiﬁcantly better than western medicine alone on improving the
outcome effective rate (RR = 1.19; 95% CI = [1.15, 1.23]; P < 0.00001).
These ﬁndings are consistent with the meta-analysis of the
duration of clinical symptoms (including fever, headache, sore
throat, stuffy nose and adenoids) which also showed that the QKL
group obtained more beneﬁts. On the basis of the above results,
QKL seemed to be an effective and safe method for the overall
effective rate and symptom resolution of uncomplicated URTIs
both in children and in adults. Subgroup analysis also revealed that
QKL combined with western medicine appeared to be more
effective than western medicine alone.
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ing Centre (CNARMC) posted a bulletin to warn the clinicians of the
potential severe ADRs of QKL [62]. Accordingly, a systematic
review was performed by Chinese Evidence-Based Medicine
Centre of Sichuan University to assess the safety of QKL [63]. A
total of 1486 cases were included in this review and they
emphasized the correct use of QKL. Finally, they drew a conclusion
that QKL has a low risk of ADRs based on current weak evidence. In
the current review, none of the included studies reported serious
ADRs related to QKL. The ADRs mainly included gastrointestinal
symptoms (such as nausea, vomiting, diarrhea and so on),
dizziness, skin itching, ﬂushing, dry mouth, insomnia fatigue
and eruption. According to the result of a pooled analysis, there
was a slightly raised risk of ADRs in control group. It was not sure
that the ADRs in an experimental group were related to QKL or the
combination of QKL and western medicine. Since nine of twenty-
six trials provided no data about ADRs, we cannot draw deﬁnitive
conclusions about the safety of QKL.
This study is the ﬁrst meta-analysis of the efﬁcacy and safety of
QKL in treating uncomplicated URTIs. We performed the review
referring to the PRISMA and AMSTAR through all stages to ensure
the research quality. Subgroup analyses were conducted to reduce
the heterogeneity. The results of this meta-analysis showed that
QKL has a therapeutic effect on uncomplicated URTIs and has less
side-effect. However, there were several limitations with this
review. Though performed a thorough search strategy in eight
electronic databases, we still cannot be absolutely certain that all
relevant trials were found. The sample size of many included trial
was small, which ranged from 57 to 230 participants. The trials
were all conducted in China and were published in Chinese. There
was no multicenter and large sample studies in our systematic
review. Only uncomplicated URTIs were included in our studies, so
conclusions regarding URTIs with complications (such as bronchi-
tis, pneumonia and so on) could not be drawn from our systematic
review. Even though all the included trials mentioned randomiza-
tion, none of them described random sequence generation.
Allocation concealment and blinding were also not mentioned
in any of the included trials. The biases of selection, detection,
implementation and publication should be taken into consider-
ation when interpreting the conclusion in this review.
5. Conclusion
The current review indicates that QKL has considerable
therapeutic effect in the treatment of uncomplicated URTIs with
no serious side effects. The results of meta-analysis showed a
positive effect of QKL plus western medicine on the overall efﬁcacy
and symptom resolution. However, we still cannot draw deﬁnitive
conclusions due to the poor methodological quality of included
studies. More high-quality RCTs would help clarify the deﬁnite
efﬁcacy and safety of QKL for treating URTIs.
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